Neighborhood Improvement Association to hold free income tax prep sessions
SAVANNAH, Ga. (WSAV) — The Neighborhood Improvement Association (NIA) and the Volunteer Income Tax Assistance (VITA) program will hold free income tax prep on Saturday, April 12.
The event will be held at the Moses Jackson Advancement Center, located on 1410 Richards Street, on Saturday from 10 a.m. to 3 p.m. NIA and VITA will also provide prep for back taxes, with years dating as far back as 2019.
This date is urgent, because anyone expecting a refund from 2021 must file by April 15th to receive the refund. According to the IRS, over 38,000 individuals in Georgia have not claimed refunds that total $33.5 million.
You will need to bring the following material to the site:
Official Photo ID for Taxpayer and Spouse
Social Security Card or ITIN letter for all on return
All W-2's and other income information, Unemployment (1099-G), Retirement (1099-R), 1099 NEC, 1099 MISC and Social Security Benefits (SSA-1099), if applicable
Healthcare Forms 1095-A (Marketplace-ACA)
Home Mortgage Interest (Form 1098)
Forms 1098-T (Education) or 1098-E (Student Loan Interest) (if applicable)
Childcare Expenses (if applicable)
IPPIN – IRS Identity Protection Pin (if applicable)
Checking & Savings account information for direct deposit.
For more information, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. 'It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon,' said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics. Dr. Mazumdar is the founding Chief Executive Officer of Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage oncology company. Prior to Bicara, Dr. Mazumdar led business development and corporate strategy at Rheos Medicines, where she supported the precision medicine company's global partnership with Roche Pharmaceuticals. Earlier in her career, she held a position at Third Rock Ventures, where she focused on company formation and business development. She holds a B.S. in biological engineering from the Massachusetts Institute of Technology and earned both an MBA from Stanford Graduate School of Business and a Ph.D. in cancer biology from Stanford School of Medicine. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what's possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics' initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit or follow us on Twitter. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics' portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection; the expected benefits resulting from the implementation of the cost saving measures and potential ability to fund key value drivers; and the expectations regarding Relay Therapeutics' use of capital and expenses. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: Relay Therapeutics' restructuring activities may be more costly or time-consuming than we expect or may not achieve their intended results; the timing, execution, and expected impact of Relay Therapeutics' restructuring plans (including the scope and timing of workforce reductions); the expected decrease in annual spending; the expected sufficiency of Relay Therapeutics' existing cash resources; the internal and external costs required for Relay Therapeutics' ongoing and planned activities, and the resulting impact on expense and use of cash, may be higher than expected, which may cause the company to use cash more quickly than expected or to change or curtail some of Relay Therapeutics' plans or both; the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; significant political, trade, or regulatory developments, such as tariffs, beyond Relay Therapeutics' control; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics' drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Relay Therapeutics' most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contact:Pete Rahmerprahmer@ Media:Dan Budwick1AB973-271-6085dan@
Yahoo
2 hours ago
- Yahoo
Social Security cost-of-living adjustment may be 2.5% in 2026, new estimate shows
The cost-of-living adjustment for Social Security could be 2.5% in 2026, based on the latest inflation data, new estimates show. That's up from last month's estimate of 2.4%, said Mary Johnson, an independent Social Security and Medicare policy analyst who forecasts 2026 COLA using monthly inflation data. A 2.5% increase would be the same gain beneficiaries received this year, but there's still time for the 2026 estimate to rise because the full impacts of President Donald Trump's tariffs are still unknown. "This estimate may rise with four more months of data still to come in before the 2026 COLA will be announced in October," Johnson said. Even though May inflation remained tame, most economists predict Trump's tariffs will raise inflation, which in turn, boosts the COLA. "Another month goes by with little evidence of tariffs, but the longer-term inflation challenge they pose remains," said Ellen Zentner, chief economic strategist for Morgan Stanley Wealth Management. Ken Kim, senior economist at KPMG, sees inflation peaking above 4% annually in the fall. That would be sharply higher than the 2.4% annual increase in the May consumer price index, a measure of average changes in goods and services costs. The average monthly Social Security check in May reached a record high $1,948.17. Based on that, a 2.5% increase would raise the monthly benefit by about $40.70. Roughly 75 million Americans, or about a fifth of the population, receive Social Security benefits. COLA is an annual adjustment to benefits meant to keep beneficiaries' purchasing power from being eroded by inflation. The final COLA for the following year is typically announced in October by the Social Security Administration. COLA is based on the percentage increase in the consumer price index for Urban Wage Earners and Clerical Workers from July through September of the last year as compared to the same three months of the current year. CPI-W tracks the overall inflation rate but can differ slightly. In May, annual CPI-W rose 2.2%, compared with the 2.4% rise in overall consumer prices. Medora Lee is a money, markets, and personal finance reporter at USA TODAY. You can reach her at mjlee@ and subscribe to our free Daily Money newsletter for personal finance tips and business news every Monday through Friday morning. This article originally appeared on USA TODAY: Social Security COLA may be 2.5% in 2026, but tariffs could lift it Sign in to access your portfolio
USA Today
3 hours ago
- USA Today
Social Security cost-of-living adjustment may be 2.5% in 2026, new estimate shows
Social Security cost-of-living adjustment may be 2.5% in 2026, new estimate shows Show Caption Hide Caption Social Security checks increasing in 2025 The Cost of Living Adjustment is rising in 2025, which will change the amount of money people will receive in their Social Security checks. Fox - 10 Phoenix The cost-of-living adjustment for Social Security could be 2.5% in 2026, based on the latest inflation data, new estimates show. That's up from last month's estimate of 2.4%, said Mary Johnson, an independent Social Security and Medicare policy analyst who forecasts 2026 COLA using monthly inflation data. A 2.5% increase would be the same gain beneficiaries received this year, but there's still time for the 2026 estimate to rise because the full impacts of President Donald Trump's tariffs are still unknown. "This estimate may rise with four more months of data still to come in before the 2026 COLA will be announced in October," Johnson said. What do tariffs have to do with COLA? Even though May inflation remained tame, most economists predict Trump's tariffs will raise inflation, which in turn, boosts the COLA. "Another month goes by with little evidence of tariffs, but the longer-term inflation challenge they pose remains," said Ellen Zentner, chief economic strategist for Morgan Stanley Wealth Management. Ken Kim, senior economist at KPMG, sees inflation peaking above 4% annually in the fall. That would be sharply higher than the 2.4% annual increase in the May consumer price index, a measure of average changes in goods and services costs. How much would a 2.5% COLA increase amount to in dollars? The average monthly Social Security check in May reached a record high $1,948.17. Based on that, a 2.5% increase would raise the monthly benefit by about $40.70. Roughly 75 million Americans, or about a fifth of the population, receive Social Security benefits. What is COLA? COLA is an annual adjustment to benefits meant to keep beneficiaries' purchasing power from being eroded by inflation. The final COLA for the following year is typically announced in October by the Social Security Administration. How is COLA calculated? COLA is based on the percentage increase in the consumer price index for Urban Wage Earners and Clerical Workers from July through September of the last year as compared to the same three months of the current year. CPI-W tracks the overall inflation rate but can differ slightly. In May, annual CPI-W rose 2.2%, compared with the 2.4% rise in overall consumer prices. Medora Lee is a money, markets, and personal finance reporter at USA TODAY. You can reach her at mjlee@ and subscribe to our free Daily Money newsletter for personal finance tips and business news every Monday through Friday morning.
